Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medicine –
Study to evaluate the combination of rociletinib (CO-1686) with
Genentech’s atezolizumab (MPDL3280A) for patients with advanced
EGFR-mutant non-small cell lung cancer
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 27, 2016--
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that it initiated a
clinical trial to evaluate a novel combination therapy of Genentech’s
investigational cancer immunotherapy atezolizumab (MPDL3280A;
anti-PD-L1) and rociletini...
Hooks, Clovis’ Vice President of Sales since 2014, has been
instrumental in building out the Company’s commercial organization
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 25, 2016--
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Dale Hooks has
been named Senior Vice President and Chief Commercial Officer. Mr. Hooks
succeeds Steve Hoerter, the Company’s current Chief Commercial Officer
and Executive Vice President, who is leaving to pursue other
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 6, 2016--
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief
Executive Officer and President, Patrick J. Mahaffy, will present at the
34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13,
2016 at 11:00 AM Pacific Time. The conference will be held at the Westin
St. Francis Hotel in San Francisco.
A live webcast of the presentation can be accessed through the investor
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.